CN106999483A - A kind of pharmaceutical composition containing quinoline or its salt - Google Patents
A kind of pharmaceutical composition containing quinoline or its salt Download PDFInfo
- Publication number
- CN106999483A CN106999483A CN201680003848.7A CN201680003848A CN106999483A CN 106999483 A CN106999483 A CN 106999483A CN 201680003848 A CN201680003848 A CN 201680003848A CN 106999483 A CN106999483 A CN 106999483A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- composition according
- alkaline matter
- arginine
- hydroxypropyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of pharmaceutical composition, contains the quinoline formyl amine of 4 [3 chlorine 4 (cyclopropylaminocarbonyl) amino-benzene oxygen] 7 methoxyl group 6 or its pharmacologically acceptable salt；And basic amino acid or meglumine, and/or selected from least one of potassium carbonate, saleratus compound；And the composition does not contain microcrystalline cellulose.
Description
The invention belongs to field of pharmaceutical preparations, specifically related to a kind of pharmaceutical composition containing quinoline 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its salt, the characteristics of said composition has that dissolution is rapid, had good stability.
WO2002032872 discloses a kind of quinoline 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl group -6- quinoline formyl amine, known its has other Angiogensis RTK related to oncogenic signals path for suppressing to participate in tumor proliferation, can also selective depression VEGF (VEGF) acceptor kinase activity, can be clinically used for the treatment of the kinds of tumors such as thyroid cancer, lung cancer, melanoma.
But, when 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmaceutically acceptable salt are prepared into pharmaceutical composition, under conditions of wet, hot presence, medicine is decomposed, pharmaceutical composition moisture absorption simultaneously, causes drug dissolution to decline.
Patent CN101001629A discloses the composition containing 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmaceutically acceptable salt, the degradation problem of medicine is solved using alkaline inorganic compounds such as magnesia, while the dissolution rate that medicine is solved using silicic acids declines problem.But silicic acids large usage quantity, silicic acids density is minimum, easily waves in production, causes the injury to operating personnel's respiratory system.Simultaneously in mixed process, because its density with other auxiliary materials differs larger, the uneven risk of material mixing is likely to result in, difficulty is caused to preparation industrialized production.
The content of the invention
Had good stability the rapid pharmaceutical composition of dissolution simultaneously it is an object of the invention to provide one kind, and pharmaceutical composition preparation technology is simple, is more suitable for the big production of technology.
The pharmaceutical composition that the present invention is provided includes active pharmaceutical ingredient and alkaline matter.Active pharmaceutical ingredient is 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmacologically acceptable salt, and described pharmaceutical composition is free of microcrystalline cellulose.
Alkaline matter includes the one or more of following substances：
(1) basic amino acid,
(2) meglumine,
(3) at least one of potassium carbonate or saleratus compound；
Wherein, basic amino acid is preferably selected from the one or more in lysine, arginine and histidine.
In a preferred embodiment of the present invention, the alkaline matter is the mixture of at least one of arginine or meglumine compound and at least one of potassium carbonate or saleratus compound.
In especially preferred embodiment of present invention, the alkaline matter is the mixture of at least one of arginine or meglumine compound and saleratus.
In another preferred embodiment of the present invention, the alkaline matter is the mixture of arginine and meglumine.
When the alkaline matter of the present invention is the mixture of two kinds of materials, the ratio of described two mixtures is not particularly limited, in preferred embodiments, and their part by weight can be 1：0.1 to 1：Between 10, preferably 1：0.5 to 1：Between 2, most preferably 1：1.
The content of the alkaline matter is unrestricted, as long as containing a small amount of above-mentioned alkaline matter, you can play raising dissolution, increases the effect of stability.For the convenience of preparation, in a preferred embodiment of the present invention, the content range of the alkaline matter can be based on composition total weight meter 0.5%-90%；It is preferred that 1%-50%；More preferably 1-35%；Most preferably 5-20%.
In the pharmaceutical composition of the present invention, the pharmacologically acceptable salt of the active component can be selected from hydrochloride, hydrobromate, tosilate, mesylate, sulfate or esilate.Gross weight based on composition, the content range of the active component can be based on composition total weight meter 0.5%-30%；It is preferred that 1%-25%；Most preferably 1-15%.
The pharmaceutical composition that the present invention is provided can contain filler, the one or more such as calcium monohydrogen phosphate, mannitol, pregelatinized starch, lactose.Gross weight based on composition, the filling agent content is about 5%~80%.
The pharmaceutical composition that the present invention is provided can contain disintegrant, and wherein disintegrant is the one or more in Ac-Di-Sol, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose and PVPP.Gross weight based on composition, the disintegrant content is about 1%~30%.
The present invention, which provides pharmaceutical composition, can contain adhesive, described adhesive may be selected from the one or more such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, methylcellulose, gross weight based on composition, described adhesive content is about 0.5~15%.
The pharmaceutical composition that the present invention is provided can also contribute to filling capsule or tabletting comprising one or more lubricants.Lubricant may be selected from talcum powder, magnesium stearate, zinc stearate, Compritol 888 ATO, NaLS, hydrogenated vegetable oil, cataloid etc..Gross weight based on composition, the content of the lubricant is about 0.5%~5%
In a preferred embodiment of the present invention, the composition is consisted of the following composition：
(1) 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmacologically acceptable salt；
(2) alkaline matter；
(3) filler；
(4) disintegrant；
(5) adhesive
(6) lubricant.
In highly preferred embodiment, the composition following component composition：
(1) 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmacologically acceptable salt；
(2) arginine, 5~20%；
(3) saleratus, 10~40%；
(4) mannitol, 30%~60%；
(5) low-substituted hydroxypropyl cellulose, 1%~10%；
(6) hydroxypropyl cellulose, 1%~5%；
(7) talcum powder, 1%~5%.
The pharmaceutical composition of the present invention can be prepared using the common method in this area, and the method such as bulk drug of pretreatment adds with interior granulation, dry granulation, one-step palletizing prepares medicament composition granule, and then filling capsule, prepares hard capsule.
The pharmaceutical composition without microcrystalline cellulose that the present invention is provided has higher stability, reduces the generation of new impurity, and with good dissolving out capability.
Fig. 1 shows stripping curve of the capsule of embodiment 1 to 3 in 0.1mol/L hydrochloric acid solutions.
Fig. 2 shows stripping curve of the capsule of embodiment 4 to 6 in 0.1mol/L hydrochloric acid solutions.
Fig. 3 shows stripping curve of the comparative example 1 to the capsule of comparative example 3 in 0.1mol/L hydrochloric acid solutions.
Fig. 4 shows the stripping curve in 0.1mol/L hydrochloric acid solutions after 40 DEG C of the capsule and temperature of embodiment 3, the placement of relative humidity 75%.
Fig. 5 shows the stripping curve in 0.1mol/L hydrochloric acid solutions after 40 DEG C of the capsule and temperature of embodiment 6, the placement of relative humidity 75%.
Fig. 6 shows the stripping curve in 0.1mol/L hydrochloric acid solutions after 40 DEG C of the capsule and temperature of comparative example 1, the placement of relative humidity 75%.
Fig. 7 shows the stripping curve in 0.1mol/L hydrochloric acid solutions after 40 DEG C of the capsule and temperature of comparative example 2, the placement of relative humidity 75%.
Fig. 8 shows the stripping curve in 0.1mol/L hydrochloric acid solutions after 40 DEG C of the capsule and temperature of comparative example 3, the placement of relative humidity 75%.
The present invention is further described by following examples and experimental example.These embodiments and experimental example being merely to illustrate property purpose, and the scope being not intended to limit the invention.
Embodiment 1~3
By mesylate (hereinafter referred to as compound A), arginine, saleratus, PEARLITOL 25C, hydroxypropyl cellulose, the low-substituted hydroxypropyl cellulose of 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl group -6- quinoline formyl amine; in the ratio in table 1; wet granulation is carried out using high-shearing granulation machine, to purify
Water is wetting agent, and wet whole grain and drying process are carried out to wet softwood, and dry particl (moisture is less than 2%) then is carried out into dry whole grain, the talcum powder of recipe quantity is added, and using rotation, always mixed machine is mixed.By obtained always mixed granule filling capsule, capsule is prepared.
Table 1
| Composition | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| Compound A | 2.5 | 4.9 | 12.3 |
| Arginine | 10.0 | 10.0 | 10.0 |
| Saleratus | 20.0 | 20.0 | 20.0 |
| PEARLITOL 25C | 56.5 | 54.1 | 46.7 |
| Hydroxypropyl cellulose | 3.0 | 3.0 | 3.0 |
| Low-substituted hydroxypropyl cellulose | 5.0 | 5.0 | 5.0 |
| Talcum powder | 3.0 | 3.0 | 3.0 |
| Amount to | 100 | 100 | 100 |
Unit：Quality %
Embodiment 4~6
By mesylate (hereinafter referred to as compound A), arginine, potassium carbonate, PEARLITOL 25C, hydroxypropyl cellulose, the low-substituted hydroxypropyl cellulose of 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl group -6- quinoline formyl amine; in the ratio in table 2; wet granulation is carried out using high-shearing granulation machine; using purified water as wetting agent; wet whole grain and drying process are carried out to wet softwood; then dry particl (moisture is less than 2%) is subjected to dry whole grain; the talcum powder of recipe quantity is added, always mixed machine is mixed using rotation.By obtained always mixed granule filling capsule, capsule is prepared.
Table 2
| Composition | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| Compound A | 2.5 | 4.9 | 12.3 |
| Arginine | 10.0 | 10.0 | 10.0 |
| Potassium carbonate | 20.0 | 20.0 | 20.0 |
| PEARLITOL 25C | 56.5 | 54.1 | 46.7 |
| Hydroxypropyl cellulose | 3.0 | 3.0 | 3.0 |
| Low-substituted hydroxypropyl cellulose | 5.0 | 5.0 | 5.0 |
| Talcum powder | 3.0 | 3.0 | 3.0 |
| Amount to | 100 | 100 | 100 |
Unit：Quality %
Comparative example 1~3
By mesylate (hereinafter referred to as compound A) arginine of 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl group -6- quinoline formyl amine, saleratus or potassium carbonate, PEARLITOL 25C, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, in the ratio in table 3, wet granulation is carried out using high-shearing granulation machine, using purified water as wetting agent, wet whole grain and drying process are carried out to wet softwood, then dry particl (moisture is less than 2%) is subjected to dry whole grain, add the talcum powder of recipe quantity, using rotation, always mixed machine is mixed.By obtained always mixed granule filling capsule, the capsule of comparative example 1~3 is prepared.
Table 3
| Composition | Comparative example 1 | Comparative example 2 | Comparative example 3 |
| Compound A | 12.3 | 12.3 | 12.3 |
| Arginine | 0 | 10 | 10 |
| Potassium carbonate | 0 | 20 | 0 |
| Saleratus | 0 | 0 | 20 |
| PEARLITOL 25C | 43.7 | 13.7 | 13.7 |
| Microcrystalline cellulose | 33 | 33 | 33 |
| Hydroxypropyl cellulose | 3 | 3 | 3 |
| Low-substituted hydroxypropyl cellulose | 5 | 5 | 5 |
| Talcum powder | 3 | 3 | 3 |
| Amount to | 100 | 100 | 100 |
Unit：Quality %
Experimental example 1：Dissolution is tested
According to two methods of annex dissolution determination second (paddle method) of Chinese Pharmacopoeia 2010 edition, dissolution determination is carried out to the capsule of embodiment 1~6.0.1mol/L hydrochloric acid solutions using 900ml carry out dissolution test as dissolution medium, and at 37 ± 0.5 DEG C with 50rpm oar speed.As a result show, in the capsule of the embodiment 1~6 containing arginine and potassium carbonate or saleratus in prescription, compound A dissolutions are complete rapidly.
Stripping curve figure is shown in Fig. 1, Fig. 2.
Experimental example 2：Dissolution is tested
According to two methods of annex dissolution determination second (paddle method) of Chinese Pharmacopoeia 2010 edition, dissolution determination is carried out to the capsule of comparative example 1~3.0.1mol/L hydrochloric acid solutions using 900ml carry out dissolution test as dissolution medium, and at 37 ± 0.5 DEG C with 50rpm oar speed.As a result show, the comparative example 1 of basic auxiliary is free of in prescription, and compound A dissolutions are slow；In prescription in the capsule of the comparative example 2 containing arginine, potassium carbonate or saleratus and comparative example 3, compound A dissolutions are complete rapidly, illustrate the addition of microcrystalline cellulose and do not influence medicine
The dissolution of thing.
Stripping curve figure is shown in Fig. 3.
Experimental example 3：Stability study
By the capsule of embodiment 3,6 and the capsule of comparative example 1~3, using high density polyethylene packaging, it is placed in the environment of 40 DEG C of temperature, relative humidity 75% and places 1 month, 2 months, 3 months, 6 months, then the generation of degradation product is determined using HPLC methods, using two methods of annex dissolution determination second (paddle method) of Chinese Pharmacopoeia 2010 edition, dissolution rate is determined to the sample after placement.
Degradation product measurement result shows, in embodiment 3 (containing arginine and saleratus), the capsule of embodiment 6 (containing arginine and potassium carbonate), degradation product does not increase, comparative example 1 is free of basic auxiliary, degradation product substantially increases with the extension of standing time, comparative example 2 and comparative example 3 contain basic auxiliary and microcrystalline cellulose, new impurity 1 is produced after being placed 1 month in the environment of 40 DEG C of temperature, relative humidity 75%, the impurity substantially increases with the extension of standing time, and other degradation products do not increase.(being shown in Table 4 to 8)
Dissolution results show, in embodiment 3 (containing arginine and saleratus), the capsule of embodiment 6 (containing arginine and potassium carbonate), compound A dissolution rate place in the environment of 40 DEG C of temperature, the relative humidity 75% after with preliminary phase ratio still without being decreased obviously, dissolution is complete.In the capsule of comparative example 1 (no basic auxiliary), compound A initial stages with the environment of 40 DEG C of temperature, relative humidity 75% place after dissolution it is incomplete, in comparative example 2, the capsule of comparative example 3, compound A dissolution rate place in the environment of 40 DEG C of temperature, the relative humidity 75% after with preliminary phase ratio still without being decreased obviously, dissolution is completely (see Fig. 4 to 8), illustrating the addition of microcrystalline cellulose does not influence dissolution, but produces impurity 1.
Table 4
Table 5
Table 6
Table 7
Table 8
Claims (19)
- A kind of pharmaceutical composition, contain 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmacologically acceptable salt, and alkaline matter, one or more of the alkaline matter selected from following substances：1) basic amino acid,2) meglumine,3) selected from least one of potassium carbonate, saleratus compound；Wherein, the composition is free of microcrystalline cellulose.
- Pharmaceutical composition according to claim 1, wherein one or more of the basic amino acid in lysine, arginine or histidine.
- Pharmaceutical composition according to claim 1, wherein the alkaline matter is meglumine.
- Pharmaceutical composition according to claim 1, wherein the basic amino acid is arginine.
- Pharmaceutical composition according to claim 1, wherein the alkaline matter is the mixture of at least one of meglumine and lysine, arginine or histidine compound.
- Pharmaceutical composition according to claim 1, wherein the alkaline matter is arginine and the mixture of at least one of potassium carbonate or saleratus compound.
- Pharmaceutical composition according to claim 1, wherein the alkaline matter is meglumine and the mixture of at least one of potassium carbonate or saleratus compound.
- Pharmaceutical composition according to claim 1, wherein the content of the alkaline matter is based on composition total weight meter 0.5%-90%；It is preferred that 1%-50%；More preferably 1-35%；Most preferably 5-20%.
- Pharmaceutical composition as claimed in any of claims 1 to 8, wherein containing disintegrant.
- Pharmaceutical composition according to claim 9, wherein disintegrant are the one or more in Ac-Di-Sol, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose and PVPP.
- Pharmaceutical composition according to claim 1 to 8 any one, described composition is made up of following composition：1) 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmacology Acceptable salt on；2) alkaline matter；3) filler；4) disintegrant；5) adhesive6) lubricant.
- Pharmaceutical composition according to claim 11, wherein described filler is selected from the one or more such as calcium monohydrogen phosphate, mannitol, pregelatinized starch, lactose, it is preferred that the filling agent content is based on composition total weight meter 5%~80%, more preferably 30%~60%.
- Pharmaceutical composition according to claim 11, one or more of the wherein described disintegrant in Ac-Di-Sol, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose and PVPP, it is preferred that its content is the gross weight meter 1%~30% based on composition, more preferably 1%~10%.
- Pharmaceutical composition according to claim 11, wherein described adhesive is selected from the one or more such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, methylcellulose, it is preferred that its content is the gross weight meter 0.5~15% based on composition, more preferably 1%~5%.
- Pharmaceutical composition according to claim 11, wherein described lubricant is selected from talcum powder, magnesium stearate, zinc stearate, Compritol 888 ATO, NaLS, hydrogenated vegetable oil, cataloid etc., gross weight based on composition, it is preferred that its content is the gross weight meter 0.5%~5% based on composition, more preferably 1%~5%.
- Pharmaceutical composition according to claim 11, it is characterised in that consist of the following composition：1) 4- [3- chloro- 4- (cyclopropylaminocarbonyl) amino-benzene oxygen] -7- methoxyl groups -6- quinoline formyls amine or its pharmacologically acceptable salt；2) arginine, 5~20%；3) saleratus, 10~40%；4) mannitol, 30%~60%；5) low-substituted hydroxypropyl cellulose, 1%~10%；6) hydroxypropyl cellulose, 1%~5%；7) talcum powder, 1%~5%.
- Pharmaceutical composition as claimed in any of claims 1 to 8, wherein pharmacologically acceptable salt is selected from hydrochloride, hydrobromate, tosilate, mesylate, sulfate or esilate.
- Pharmaceutical composition according to claim 17, wherein pharmacologically acceptable salt is mesylate.
- Purposes of the pharmaceutical composition in the medicine for preparing treating cancer according to any one in claim 1 to 18；The preferred thyroid cancer of cancer, lung cancer or melanoma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015105061612 | 2015-08-17 | ||
| CN201510506161 | 2015-08-17 | ||
| PCT/CN2016/091717 WO2017028660A1 (en) | 2015-08-17 | 2016-07-26 | Pharmaceutical composition containing quinoline derivative or salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106999483A true CN106999483A (en) | 2017-08-01 |
| CN106999483B CN106999483B (en) | 2019-05-03 |
Family
ID=58050460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680003848.7A Active CN106999483B (en) | 2015-08-17 | 2016-07-26 | A kind of pharmaceutical composition containing quinoline or its salt |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN106999483B (en) |
| TW (1) | TWI739756B (en) |
| WO (1) | WO2017028660A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068620A (en) * | 2022-07-20 | 2022-09-20 | 天津睿创康泰生物技术有限公司 | Pharmaceutical composition capable of reducing generation of arylamine impurities |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3384901B1 (en) * | 2017-04-04 | 2024-08-14 | Synthon B.V. | Pharmaceutical composition comprising lenvatinib mesylate |
| US10583133B2 (en) | 2018-03-12 | 2020-03-10 | Shilpa Medicare Limited | Pharmaceutical compositions of lenvatinib |
| CN115397416B (en) * | 2020-05-09 | 2023-12-05 | 北京睿创康泰医药研究院有限公司 | Pharmaceutical composition containing molecular level of lenvatinib, preparation method and application thereof |
| EP4147689A1 (en) * | 2021-09-13 | 2023-03-15 | Lotus Pharmaceutical Co., Ltd. | Lenvatinib formulation |
| EP4424303A1 (en) * | 2023-02-28 | 2024-09-04 | Stada Arzneimittel Ag | Lenvatinib composition with improved bioavailability |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001629A (en) * | 2004-09-17 | 2007-07-18 | 卫材R&D管理有限公司 | Medicinal composition |
| CN102470133A (en) * | 2009-08-19 | 2012-05-23 | 卫材R&D管理有限公司 | Quinoline derivative-containing pharmaceutical composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101526A1 (en) * | 2003-04-22 | 2004-11-25 | Eisai Co., Ltd. | Polymorphous crystal of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-qunolinecarboxamide and method for preparation thereof |
| WO2007052849A1 (en) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| TWI501950B (en) * | 2011-02-09 | 2015-10-01 | Eisai R&D Man Co Ltd | Pharmaceutical composition comprising quinoline derivative |
-
2016
- 2016-07-26 WO PCT/CN2016/091717 patent/WO2017028660A1/en active Application Filing
- 2016-07-26 CN CN201680003848.7A patent/CN106999483B/en active Active
- 2016-08-10 TW TW105125414A patent/TWI739756B/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001629A (en) * | 2004-09-17 | 2007-07-18 | 卫材R&D管理有限公司 | Medicinal composition |
| CN102470133A (en) * | 2009-08-19 | 2012-05-23 | 卫材R&D管理有限公司 | Quinoline derivative-containing pharmaceutical composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068620A (en) * | 2022-07-20 | 2022-09-20 | 天津睿创康泰生物技术有限公司 | Pharmaceutical composition capable of reducing generation of arylamine impurities |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106999483B (en) | 2019-05-03 |
| TWI739756B (en) | 2021-09-21 |
| TW201707702A (en) | 2017-03-01 |
| WO2017028660A1 (en) | 2017-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106999483A (en) | A kind of pharmaceutical composition containing quinoline or its salt | |
| JP5401327B2 (en) | Tablets with improved dissolution | |
| EP1884242A1 (en) | Pharmaceutical composition | |
| CN105287411A (en) | Perampanel dispersible tablet and preparation method thereof | |
| CN106139156B (en) | A kind of pharmaceutical composition containing quinoline or its salt | |
| CN112220770B (en) | Pharmaceutical composition of selepag and preparation method thereof | |
| EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| EP2295040A1 (en) | Pharmaceutical compositions of pramipexole | |
| KR20160002177A (en) | Pharmaceutical composition comprising oseltamivir free base | |
| JPWO2017047586A1 (en) | tablet | |
| EP3052130B1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| JP2017520619A (en) | Ceritinib formulation | |
| JP6407084B2 (en) | Tablet and production method thereof | |
| JP2010265211A (en) | Coated caffeine particle and solid preparation for oral administration containing the same | |
| KR102468610B1 (en) | Pharmaceutical dosage forms | |
| EP3378478B1 (en) | Pharmaceutical composition comprising quinoline derivative or salt thereof | |
| US10328076B2 (en) | Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof | |
| JP6199922B2 (en) | Irbesartan-containing tablets with improved chemical stability | |
| CN104095850B (en) | A kind of stable Pitavastatin calcium medicine compound and preparation method thereof | |
| JP2016190794A (en) | Tablet and method for producing the same | |
| JP2016138073A (en) | Silodosin-containing tablet in which stability is improved | |
| KR20230152960A (en) | A single-layered composite tablet comprising dapagliflozin and citagliptin | |
| CN114845723A (en) | Pharmaceutical composition comprising quinazoline derivative or salt thereof | |
| CN117241789A (en) | Pharmaceutical composition | |
| EA041427B1 (en) | PHARMACEUTICAL DOSAGE FORMS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210611 Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd. Patentee after: Shanghai maijin Biomedical Technology Co.,Ltd. Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd. |
|
| TR01 | Transfer of patent right |